Health TrialsbyHealthPanel

Glycated Hbg Index and RDW as Prognstic Indicator in Critical Ill Patients

ConditionCritical Ill Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorAssiut University

About this trial

The aim of this study was to evaluate the impact of GHI and RDW as prognostic indicator in critically ill Patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients admitted to Critical and Intermediate Care Units in Internal Medicine Department after history taking, examination and diagnosis

diabtic Patients 3-animic Patients

Disqualifiers

Patients under 18 years of age

ICU stay < 24 h

patients without HbA1c, FBG, or RDW data or anything's that's affect the HbA1c .

Trial population

All patients except patients in exculcion critira

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Hbg and RDW

    Device

    Hbg and RDW as prognstic indicator in critical ill patients

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Glycated Hemoglobin level

Measurement of Hb level in all patients upon ICU admission.

Time frame
Baseline
2

Red Cell Distribution Width (RDW)

Measurement of RDW in all patients upon ICU admission.

Time frame
baseline
3

Hemoglobin (Hb) Level

Measurement of Hb level in all patients upon ICU admission.

Time frame
baseline

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: